158 related articles for article (PubMed ID: 37563073)
1. Circulating tumor DNA in NK/T and peripheral T cell lymphoma.
Huo YJ; Zhao WL
Semin Hematol; 2023 Jul; 60(3):173-177. PubMed ID: 37563073
[TBL] [Abstract][Full Text] [Related]
2. Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas.
Kim SJ; Kim YJ; Yoon SE; Ryu KJ; Park B; Park D; Cho D; Kim HY; Cho J; Ko YH; Park WY; Kim WS
Cancer Res Treat; 2023 Jan; 55(1):291-303. PubMed ID: 35240014
[TBL] [Abstract][Full Text] [Related]
3. [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].
Peng YL; Huang HQ; Lin XB; Xia ZJ; Li YH; Wang W; He YJ; Pan ZH; Jiang WQ; Guan ZZ
Ai Zheng; 2004 Aug; 23(8):943-6. PubMed ID: 15301720
[TBL] [Abstract][Full Text] [Related]
4. Mutation profiling, tumour burden assessment, outcome prediction and disease monitoring by circulating tumour DNA in peripheral T-cell lymphoma.
Wei C; Wang W; Zhang Y; Zhao D; Zhang W; Zhou D
Br J Haematol; 2023 Jul; 202(1):86-95. PubMed ID: 37132364
[TBL] [Abstract][Full Text] [Related]
5. The aggressive peripheral T-cell lymphomas: 2013.
Armitage JO
Am J Hematol; 2013 Oct; 88(10):910-8. PubMed ID: 24078271
[TBL] [Abstract][Full Text] [Related]
6. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.
Abramson JS; Feldman T; Kroll-Desrosiers AR; Muffly LS; Winer E; Flowers CR; Lansigan F; Nabhan C; Nastoupil LJ; Nath R; Goy A; Castillo JJ; Jagadeesh D; Woda B; Rosen ST; Smith SM; Evens AM
Ann Oncol; 2014 Nov; 25(11):2211-2217. PubMed ID: 25193992
[TBL] [Abstract][Full Text] [Related]
7. Next-generation sequencing-based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCL.
Miljkovic MD; Melani C; Pittaluga S; Lakhotia R; Lucas N; Jacob A; Yusko E; Jaffe ES; Wilson WH; Roschewski M
Blood Adv; 2021 Oct; 5(20):4198-4210. PubMed ID: 34432874
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor DNA by high-throughput sequencing of T cell receptor monitored treatment response and predicted treatment failure in T cell lymphomas.
Zhang W; Wang W; Han X; Gan Y; Qian L; Zhang Y; Zhang C; Wang Y; Guan Y; Yang L; Zhou D
Int J Lab Hematol; 2021 Oct; 43(5):1041-1049. PubMed ID: 33734593
[TBL] [Abstract][Full Text] [Related]
9. Effects of first-line chemotherapy on natural killer cells in adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
Ogura M; Ishida T; Tsukasaki K; Takahashi T; Utsunomiya A
Cancer Chemother Pharmacol; 2016 Jul; 78(1):199-207. PubMed ID: 27289375
[TBL] [Abstract][Full Text] [Related]
10. The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management.
Armitage JO
Am J Hematol; 2012 May; 87(5):511-9. PubMed ID: 22508369
[TBL] [Abstract][Full Text] [Related]
11. Expression of cytotoxic proteins in peripheral T-cell and natural killer-cell (NK) lymphomas: association with extranodal site, NK or Tgammadelta phenotype, anaplastic morphology and CD30 expression.
Kanavaros P; Boulland ML; Petit B; Arnulf B; Gaulard P
Leuk Lymphoma; 2000 Jul; 38(3-4):317-26. PubMed ID: 10830738
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma.
Zhang P; Zhang M
Clin Epigenetics; 2020 Nov; 12(1):169. PubMed ID: 33160401
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
Coiffier B; Federico M; Caballero D; Dearden C; Morschhauser F; Jäger U; Trümper L; Zucca E; Gomes da Silva M; Pettengell R; Weidmann E; d'Amore F; Tilly H; Zinzani PL
Cancer Treat Rev; 2014 Oct; 40(9):1080-8. PubMed ID: 25199959
[TBL] [Abstract][Full Text] [Related]
14. The aggressive peripheral T-cell lymphomas: 2015.
Armitage JO
Am J Hematol; 2015 Jul; 90(7):665-73. PubMed ID: 26031230
[TBL] [Abstract][Full Text] [Related]
15. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas.
Zinzani PL; Bonthapally V; Huebner D; Lutes R; Chi A; Pileri S
Crit Rev Oncol Hematol; 2016 Mar; 99():214-27. PubMed ID: 26811013
[TBL] [Abstract][Full Text] [Related]
16. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification.
Savage KJ; Chhanabhai M; Gascoyne RD; Connors JM
Ann Oncol; 2004 Oct; 15(10):1467-75. PubMed ID: 15367405
[TBL] [Abstract][Full Text] [Related]
17. All-oral metronomic DEVEC schedule in elderly patients with peripheral T cell lymphoma.
Cox MC; Banchi M; Pelliccia S; Di Napoli A; Marcheselli L; Patti C; Anticoli Borza P; Battistini R; Di Gregorio F; Orlandi P; Bocci G
Cancer Chemother Pharmacol; 2020 Dec; 86(6):841-846. PubMed ID: 33070248
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic challenges in peripheral T-cell lymphoma.
Luan Y; Li X; Luan Y; Luo J; Dong Q; Ye S; Li Y; Li Y; Jia L; Yang J; Yang DH
Mol Cancer; 2024 Jan; 23(1):2. PubMed ID: 38178117
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of extra-nodal NK/T-cell lymphoma and peripheral T-cell lymphoma: significant differences in clinical characteristics and prognosis.
Lim ST; Hee SW; Quek R; Lim LC; Yap SP; Loong EL; Sng I; Tan LH; Ang MK; Ngeow J; Tham CK; Ngo L; Tan MH; Tao M
Eur J Haematol; 2008 Jan; 80(1):55-60. PubMed ID: 18028433
[TBL] [Abstract][Full Text] [Related]
20. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.
Gkotzamanidou M; Papadimitriou CA
Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
